Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple MyelomaJesús F. San Miguel, Hermann Einsele, Carlos Fernández de Larrea et al.|New England Journal of Medicine|2023Cited by 719
OA-45 Pharmacokinetic and correlative analysis of ciltacabtagene autoleucel in patients with lenalidomide-refractory multiple myeloma in the CARTITUDE-4 trialCarlos Fernández de Larrea, Christopher Strouse, Simon J. Harrison et al.|Clinical Lymphoma Myeloma & Leukemia|2023Cited by 3
Efficacy and Safety in Patients with Lenalidomide-Refractory Multiple Myeloma and 1–3 Prior Lines Who Received a Single Infusion of Ciltacabtagene Autoleucel As Study Treatment in the Phase 3 Cartitude-4 TrialM Hasib Sidiqi, Kwee Yong, Paolo Corradini et al.|Transplantation and Cellular Therapy|2024Cited by 1